Connect to share and comment

Pharma giant Novartis sees net profit jump 24%

Swiss pharmaceuticals giant Novartis on Thursday posted a 24-percent jump in first-quarter net profit, driven largely by the sale of a blood transfusion diagnostics unit. The company, which earlier this week announced an extreme make-over of its structure, said it had raked in a net profit of $2.96 billion (2.14 billion euros) during the first three months of the year.

Novartis and GSK trade assets as pharma industry reshapes

By Caroline Copley and Paul Sandle ZURICH/LONDON (Reuters) - Novartis and GlaxoSmithKline agreed to trade more than $20 billion worth of assets on Tuesday to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition.

In latest cycle, drugmakers use deals to narrow focus to boost prospects, satisfy shareholders

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

In latest round of change in pharmaceuticals industry, Novartis inks deals with GSK and Lilly

GENEVA - Swiss pharmaceutical firm Novartis AG launched a major overhaul of its business Tuesday, unveiling a series of multibillion-dollar deals with Britain's GlaxoSmithKline PLC and the U.S.'s Eli Lilly

Shake-up in pharma world as Novartis, GSK announce mega-deals

Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, unveiling multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures by the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector, GSK boost its share in vaccines and Eli Lilly strengthen its animal health unit.

Huge pharma sector manoeuvres boost European stocks

Huge deal-making in the pharmaceutical sector gave European stocks a shot in the arm on Tuesday, even though tension over the crisis in Ukraine lurked in the background, traders said. Shares in European pharmaceutical groups surged owing to a major reshaping of the sector, driven by Novartis of Switzerland and GlaxoSmithKline in London. London's FTSE 100 gained 0.85 percent to 6,681.76 points compared to Thursday's closing level -- the last trading day before European markets closed for Easter.

Novartis sees GSK's cancer drugs as potential blockbusters

ZURICH (Reuters) - Novartis believes GlaxoSmithKline's cancer drugs Votrient, Tafinlar and Mekinist could have more than $1 billion in sales each, the head of the Swiss company's pharmaceutical unit said on Tuesday. "We believe Votrient, Tafinlar, Mekinist - assuming the (combination) trial is positive for overall survival - all three of these products could become blockbusters in our hands," David Epstein told an investor call.

Huge pharma sector manoeuvres boost European stocks

Huge deal-making in the pharmaceutical sector pushed up European stocks on Tuesday, even though tension over the crisis in Ukraine lurked in the background, traders said. Shares in European pharmaceutical groups surged owing to a major reshaping of the sector, driven by Novartis of Switzerland and GlaxoSmithKline in London. London's benchmark FTSE 100 index climbed 0.79 percent to 6,677.55 points compared with Thursday's closing level -- the last trading day before European markets closed for Easter.

Novartis revamps pharma world with mega-deals with GSK, Eli Lilly

Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, revealing multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures involving the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector and GSK seizing the chance to boost its share in vaccines.

Novartis revamps pharma world with mega-deals with GSK, Eli Lilly

Drugmakers Novartis and GlaxoSmithKline announced an extreme makeover Tuesday, revealing multi-billion-dollar deals also involving US group Eli Lilly in a major shakeup of the pharmaceutical sector. The string of takeovers and ventures involving the three giant healthcare groups will see Novartis sharpen its focus on the high-grossing cancer sector and GSK seizing the chance to boost its share in vaccines.
Syndicate content